ContinUse Biometrics (also known as Donisi Health)

Tel Aviv, Israel All Israel companies → — Founded 2015

Medical Device / Hardware Specialty-Focused AI Wearables / RPM

Series B

Website Claim this company

Products

Gili Pro BioSensor (also known as Gili BioSensor System)

ContinUse Biometrics (also known as Donisi Health)

Cardiology AI

ContinUse Biometrics (Donisi Health) offers the Gili Pro BioSensor, an FDA-cleared, contactless optical system that uses AI to remotely measure heart and respiratory rates for healthcare professionals in clinical and research settings.

See all 1 product →

About ContinUse Biometrics (also known as Donisi Health)

Donisi Health, a spin-off of ContinUse Biometrics, is a MedTech company focused on providing user-friendly, in-home health detection solutions for patients with chronic cardiopulmonary diseases, particularly congestive heart failure (CHF). The company’s core technology is an FDA-cleared, patented AI-based system that utilizes contact-free biosensors to detect and analyze multiple health bio-indicators simultaneously. This technology delivers clinically meaningful insights without the need for wires, wearables, or patches, aiming to optimize care and prevent rehospitalization.

For physicians, Donisi Health offers a pre-emptive approach to monitoring multiple cardiac and pulmonary biomarkers, such as pulmonary congestion (lung fluid content), which is crucial for the timely detection of heart failure deterioration. The system’s ability to remotely detect signs of pulmonary congestion and other bio-parameters at home allows for early intervention by healthcare teams, potentially reducing costly rehospitalizations for CHF patients. The Gili Pro BioSensor, an FDA-cleared device, uses optical sensors and AI algorithms to remotely monitor surface-level micro-vibrations associated with internal organs, providing medical-grade accuracy across diverse patient demographics. Donisi Health’s technology supports the continuum of care from hospital to home, offering a scalable solution for managing patients with multiple chronic conditions and co-morbidities.

What Physicians Need to Know

Specialization

Donisi Health (formerly ContinUse Biometrics) specializes in user-friendly, in-home health detection solutions, primarily for patients with congestive heart failure (CHF) and other chronic cardiopulmonary diseases. Their core focus is on optimizing care and preventing rehospitalization through remote patient monitoring.

Key Differentiators

Their primary differentiator is their FDA-cleared, patented AI-based system that uses contact-free biosensors. This technology detects and analyzes multiple health bio-indicators simultaneously without wires, wearables, patches, or even needing to remove clothing. It can remotely detect signs of pulmonary congestion, a key indicator of CHF exacerbation, with medical-grade accuracy. The system also maintains accuracy across different body shapes and skin tones.

Technology Stack

Donisi Health's technology relies on a combination of proprietary optics, algorithms, and artificial intelligence. It remotely detects and analyzes surface-level micro-vibrations caused by the workings of internal organs like the heart and lungs. The system processes this data in the cloud using proprietary algorithms and AI to deliver clinically meaningful insights. Their Gili Biosensor System is a tabletop device that can transmit collected data to a telehealth or senior care provider via a mobile app and online platform.

Regulatory Status

Donisi Health received FDA De Novo clearance for its Gili Biosensor System in June 2022, making it the first to bring this innovative contact-free multiparameter measurement technology to the medical market. They have also undergone the FDA Presubmission process for the identification of atrial fibrillation (AFib) and plan for additional submissions.

Physician Tip

For physicians, Donisi Health offers a preemptive approach to cardiac and pulmonary health monitoring, enabling early detection of changes in key health indicators like pulmonary congestion. This can help optimize care, reduce rehospitalization rates for CHF patients, and provide a safety net for those with chronic conditions. The contact-free nature of the technology means less burden on patients, potentially leading to better adherence to monitoring. The system provides clinically meaningful insights and notifications, aiding in timely intervention.

Donisi Health's system can transmit collected data to telehealth or senior care providers via a mobile app and online platform. While specific EHR integrations are not explicitly detailed in the provided information, their B2B2C go-to-market strategy suggests potential partnerships with RPM providers and 'hospital at home' services.

Products by ContinUse Biometrics (also known as Donisi Health)

1 product in the directory

Gili Pro BioSensor (also known as Gili BioSensor System)

ContinUse Biometrics (also known as Donisi Health)

Cardiology AI

What the Web Says

Donisi Health, formerly ContinUse Biometrics, is a MedTech company that has developed a contact-free health monitoring system. Their FDA-cleared Gili Pro BioSensor system uses optical sensors and AI to remotely measure vital signs like pulse and respiratory rate, even through clothing and from a distance. The company aims to provide continuous health monitoring from hospital to home, with ongoing development for detecting conditions like atrial fibrillation and pulmonary congestion.

Overall: Positive

Strengths

Contact-free vital sign monitoring, eliminating the need for wires or patches.
Ability to measure vital signs through clothing and from several feet away.
FDA De Novo clearance for its Gili Pro BioSensor system.
Utilizes AI and algorithms for analyzing measurements and detecting abnormalities.
Potential to bridge the gap between hospital and home care.
Ongoing development for detecting additional cardiopulmonary parameters like atrial fibrillation and pulmonary congestion.

Limitations

Limited publicly available product reviews from G2, Capterra, or Reddit specific to Donisi Health's devices.
Lack of detailed employer reviews on Glassdoor specific to ContinUse Biometrics/Donisi Health.
Some general biometric companies on Indeed have mixed employee reviews regarding management and benefits.
General challenges with healthcare IT software can include integration difficulties and user interface issues.
Reddit discussions on healthcare technology are broad and do not specifically mention Donisi Health.

Based on reviews from: fiercebiotech.com, g2.com, indeed.com, pacermonitor.com, researchgate.net, iowaworkcomp.gov, kcl.ac.uk, mobihealthnews.com, prnewswire.com, mdpi.com, trustpilot.com, biu.ac.il, nih.gov, capterra.com, reddit.com

Last updated: 2026-10-27

Videos

News, demos, and interviews about ContinUse Biometrics (also known as Donisi Health).

Loading videos...

Videos load interactively. If none appear, search YouTube for ContinUse Biometrics (also known as Donisi Health) →

View all on YouTube

Press & Coverage

prnewswire.com

Donisi Health Presents Data at ACC22 Demonstrating Accuracy of a Contact-Free Medical Device that Detects Pulmonary Congestion in CHF Patients at Home

Donisi Health announced results from a clinical study at ACC22, showcasing the efficacy of its contact-free technology in detecting pulmonary congestion in congestive heart failure (CHF) patients at home. The study highlights the potential for Donisi's remote monitoring solution to help prevent re-hospitalizations by enabling timely intervention.

2022-04

prnewswire.com

FDA Grants Donisi De Novo Clearance for Innovative Contact-Free Multiparameter Health Sensing Solution

The U.S. Food and Drug Administration (FDA) granted Donisi's contact-free multiparameter measurement system de novo clearance, making it the first such innovative technology to enter the medical market. This clearance allows Donisi to remotely detect and analyze surface-level micro-vibrations caused by internal organs like the heart and lungs.

2021-04

startupnationcentral.org

Donisi Health Gets FDA's De Novo Clearance for Its Gili Biosensor System

Donisi Health received FDA De Novo clearance for its Gili Biosensor System in June 2022, a significant regulatory approval validating the company's contact-free technology for in-home cardiac and pulmonary health monitoring. This clearance signals the system's readiness for broader market adoption, particularly for patients with chronic conditions.

2022-06

globes.co.il

Medical monitoring co ContinUse Biometrics raises $20m

ContinUse Biometrics announced a $20 million Series B financing round led by the Chartered Group, bringing its total funding to $27 million. The Tel Aviv-based company focuses on revolutionizing sensing solutions through groundbreaking research and advanced AI techniques.

2018-03

sciprofiles.com

A Contact-Free Optical Device for the Detection of Pulmonary Congestion—A Pilot Study

A pilot study assessed a new contact-free optical medical device, the Gili system, for the early detection of lung congestion in heart failure patients. The study found the device to be effective, with an algorithm developed using machine learning techniques showing high accuracy.

2022-10

biu.ac.il

Accuracy of a novel contact-free optical system for monitoring heart and respiratory rate

A study evaluated the accuracy of a new contact-free optical system for monitoring heart and respiratory rate, demonstrating over 99% accuracy. This technology addresses the growing need for remote patient monitoring without requiring constant physical contact.

2021-07

otv.vc

Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition

Donisi Health won first place in the Innovations in Cardiovascular Intervention Competition, highlighting its advancements in cardiovascular technology. This recognition further solidifies the company's position as an innovator in the medical field.

2022-04

prnewswire.com

Donisi Health Named 2021's "Future Unicorn" by E&T Magazine

E&T Magazine, the official publication of the Institution of Engineering and Technology (IET), awarded Donisi Health the "Future Unicorn" title in 2021. This award recognizes Donisi Health's potential for significant growth and impact in the industry.

2021-12

Frequently Asked Questions

What specific AI products does Donisi Health offer for healthcare, and what are their primary functions?

Donisi Health, formerly ContinUse Biometrics, offers the Gili Pro BioSensor system, an FDA-cleared, AI-based, contact-free technology. This system remotely monitors surface-level micro-vibrations to estimate pulse rate, heart rate, and respiratory rate. The company's primary focus is on providing in-home health detection solutions for patients with congestive heart failure (CHF) and other chronic diseases, aiming to optimize care and prevent rehospitalization by detecting changes in key health indicators like pulmonary congestion.

How does Donisi Health ensure compliance with healthcare regulations like HIPAA and medical device regulations for its AI products?

Donisi Health's Gili Pro BioSensor system has received FDA De Novo clearance, signifying its compliance as a medical device. The company's technology is backed by multiple granted patents and is clinically validated, maintaining medical-grade accuracy. While specific details about HIPAA compliance are not explicitly stated in the provided information, AI in healthcare generally operates within a layered compliance environment that includes privacy laws like HIPAA.

What is the pricing model for Donisi Health's AI solutions, and are there different tiers for various healthcare settings (e.g., hospitals, clinics, home care)?

While specific pricing details are not publicly available, Donisi Health's solutions are described as subscription-based, partnering with Remote Patient Monitoring (RPM) providers and 'Hospital at Home' programs. This suggests a service-oriented model rather than a one-time purchase, likely adaptable to different healthcare settings focused on remote monitoring.

What kind of support does Donisi Health provide to healthcare professionals and administrators for implementing and utilizing their AI platforms?

Donisi Health's system allows users to control the sensor and view near real-time measurement results through a connected mobile application. The company aims to provide clinically meaningful insights and notifications of changes in key health indicators. While detailed support structures are not outlined, the focus on user-friendly, in-home solutions implies a need for accessible support for both patients and healthcare providers.

What partnerships does Donisi Health have with other healthcare organizations, research institutions, or technology providers?

Donisi Health has collaborated with the Cardiovascular Research Center at the Tel Aviv Sourasky Medical Center for developing solutions to measure and detect cardiopulmonary parameters like pulmonary congestion. They also received a BIRD grant in partnership with Dell Technologies. The company partners with RPM providers and 'Hospital at Home' services for their subscription-based model.

What is the company stability of Donisi Health, including funding, market position, and long-term viability?

Donisi Health was founded in March 2015 and has raised a total of $27.2 million across 6 funding rounds from 5 investors. They received FDA De Novo clearance for their Gili Biosensor System in June 2022 (and previously in April 2021 for the Gili Pro BioSensor system), a significant validation of their technology. The company has been recognized as an "Innovation Leader" and a "Future Unicorn," indicating a strong market position and potential for growth.

Related Companies

Suggest an Edit → | Report an issue